Latest News about CRSP
Recent news which mentions CRSP
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'
May 10, 2023
From Benzinga
Why CRISPR Therapeutics Stock Is on Fire Today
May 09, 2023
From Motley Fool
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
May 06, 2023
From Motley Fool
From Motley Fool
3 Top Healthcare Stocks to Buy in May
May 04, 2023
From Motley Fool
From Motley Fool
From InvestorPlace
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
April 24, 2023
From Benzinga
The Best Stocks to Invest $20,000 in Right Now
April 23, 2023
From Motley Fool
Buy the Dip: 2 Top Stocks to Snatch Up Now
April 23, 2023
From Motley Fool
3 Stocks With Huge Catalysts on the Way
April 22, 2023
From Motley Fool
2 Growth Stocks That Could Keep Growing for Decades
April 21, 2023
From Motley Fool
Better Big Biotech Buy: Biogen vs. Vertex
April 20, 2023
From Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
April 20, 2023
From InvestorPlace
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
April 20, 2023
From Benzinga
3 High-Growth Biotech Stocks Poised for Success in 2023
April 18, 2023
From InvestorPlace
The Top Healthcare Stocks to Buy With $100
April 18, 2023
From Motley Fool
Why CRISPR Therapeutics Stock Is Marching Higher Today
April 17, 2023
From Motley Fool
Why Shares of Editas Medicine Rose Monday
April 17, 2023
From Motley Fool
Better Growth Stock: Axsome vs. CRISPR Therapeutics
April 16, 2023
From Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
April 14, 2023
From Motley Fool
Tickers
CRSP
From InvestorPlace
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
April 13, 2023
From InvestorPlace
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst
April 13, 2023
Tickers
CRSP
From Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
April 13, 2023
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.